ArticleEndocrinology, diabetes & metabolism case reports2025
Effects of lanreotide autogel immediately after a single injection for thyrotropin-producing pituitary tumor.
Article in Endocrinology, diabetes & metabolism case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: We present the case of a 51-year-old man who was referred to our hospital due to abnormal thyroid function tests. Laboratory evaluations showed elevated serum free (F) T3 and free (F) T4 levels (9.05 pg/mL and 4.21 ng/dL, respectively), with a normal serum thyroid-stimulating hormone (TSH) level of 1.49 μIU/mL, indicating central hyperthyroidism. An 18 × 17 × 14 mm T1-weighted hypointense tumor was found on the left side of the pituitary gland, with low contrast enhancement during a cranial MRI. The TRH stimulation test revealed no TSH response. The administration of a single dose of octreotide reduced TSH levels. Following these findings, the patient was clinically diagnosed with a TSH-producing pituitary tumor (TSHoma). The patient was directed to our hospital's neurosurgery department for pituitary surgery and began preoperative treatment with lanreotide autogel (90 mg, subcutaneous injection). Four days after administration, FT3 and FT4 levels returned to normal. Seven days after administration, an MRI revealed a 50% reduction in tumor volume. Endoscopic pituitary surgery was performed 15 days after the initial administration and resulted in complete tumor resection. A histopathological examination confirmed the presence of a TSH-producing pituitary neuroendocrine tumor. Postoperatively, FT3 and FT4 levels stayed within the normal ranges. This case demonstrates how a single dose of lanreotide autogel not only normalized thyroid hormone levels but also resulted in rapid shrinkage of the pituitary tumor in TSHoma. Learning points: Preoperative treatment with somatostatin analogs for TSH-producing pituitary adenomas (TSHomas) aims to control thyroid function, preventing thyroid storm during surgery, and to reduce tumor size. We report a case of a TSHoma treated preoperatively with a single subcutaneous injection of lanreotide autogel (LAN-ATG). In this patient, thyroid function normalized and significant tumor shrinkage was observed within 1 week of LAN-ATG administration. This case demonstrates that significant therapeutic effects can be achieved within days after a single injection of LAN-ATG. This approach could facilitate earlier surgical intervention, potentially improving patient outcomes and optimizing preoperative management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.